We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sysquant® Awarded Two Contracts

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Sysquant® Awarded Two Contracts"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The board is pleased to announce that the further assessment of an additional 20 cases of pancreatic cancer using SysQuant® has recently been completed. The results validate the findings from the first 12 cases that were published earlier this year in PLOS ONE. As well as potential new drug targets, a key outcome of this study is a set of new biomarkers predicting the likelihood and timescale of tumour recurrence after surgery and the ability to match patients to individual drug treatments. Proteome has already filed patent applications around these markers.

The recent integration of the Orbitrap fusion mass spectrometer with our new IT installation has resulted in a 4x increase in protein detection in less than quarter of the time taken compared to the original study.

The application of SysQuant® in neurodegeneration has also been expanded through  collaboration with a leading academic group to study the changes in cell signalling related to tau pathology in Alzheimer’s disease. As with the pancreatic cancer study this is expected to identify novel biomarkers and new drug targets. We expect publication of these results in 2015.

In a separate study the Company is combining SysQuant® with its patented TMT®calibrator workflow to enhance discovery of biomarkers for Alzheimer’s disease. A preliminary study has just been completed which has identified more than 100 additional brain proteins that may serve as biomarkers in cerebrospinal fluid. Translation of these into blood is now anticipated in 2015.

SysQuant® is attracting strong interest from pharmaceutical companies and we are pleased to confirm that it has been awarded two contracts in the last fortnight, including proof of concept studies, with further contracts in negotiation.